Scientist Learns HIV Prevention Needs More Than Lab Results

Brian Munansangu thought he understood his work studying HIV and tuberculosis until his aunt asked him a simple question around a fire in rural Zambia.

She wanted to know if the new HIV cure was available yet. The problem? There was no cure, and the injection she heard about wasn't meant for her at all.

Munansangu had returned home to Chisamba for Christmas 2025, fresh from his postdoctoral research in South Africa. Zambia had just received its first shipments of lenacapavir, a groundbreaking twice-yearly injection that prevents HIV infection.

His aunt had lived with HIV for a decade. She took her antiretroviral drugs faithfully, never missed clinic appointments, and had access to healthcare workers for questions.

Yet she believed lenacapavir could cure her HIV. A WhatsApp video had convinced her that a cure existed and was coming to Zambia.

If someone this connected to HIV care didn't understand the difference between prevention and treatment, what about everyone else in her community? That question shifted something in Munansangu.

He explained that lenacapavir gives people without HIV nearly perfect protection for six months at a time. The medication slowly releases in the body, preventing new infections before they happen.

For his aunt, already living with HIV, the injection offered nothing. Her antiretrovirals were her treatment.

The confusion about a cure came from real cases, but they weren't replicable treatments. A handful of people had been cured through risky stem cell transplants for blood cancers, receiving donor cells with a rare genetic mutation that also blocks HIV.

Remarkable science, but not a solution for the 40.9 million people worldwide living with HIV.

Why This Inspires

Lenacapavir's clinical trials showed unprecedented protection rates. But Munansangu realized that publishing papers wasn't enough anymore.

The injection offers people freedom from daily pills, providing greater privacy and dignity. In communities where being seen at a clinic or carrying medication can cost you socially, a twice-yearly injection could mean the difference between consistent prevention and none at all.

Many African countries have made enormous progress getting people with HIV onto treatment. But prevention still depends on trust, and trust requires understanding.

That evening changed how Munansangu saw his role as a scientist. He could explain T-cell activation and cytokine signaling to graduate students all day, but he hadn't been prepared to answer his aunt's simple, urgent questions.

Knowledge trapped in journals can't protect anyone. It has to travel the same dusty roads people do, sit beside them at fires, and answer the questions they ask after watching videos on their phones.

Scientific breakthroughs only change lives when they're matched by clear communication that reaches the communities they're designed to protect.